RESEARCH ARTICLE

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma

Amit Kumar1, Claire E. P. Smith1, Elena E. Giorgi2, Joshua Eudailey1, David R. Martinez1, Karina Yusim2, Ayooluwa O. Douglas1, Lisa Stamper1, Erin McGuire1, Celia C. LaBranche3, David C. Montefiori3, Genevieve G. Fouda1, Feng Gao4,5, Sallie R. Permar1,*

1 Duke Human Vaccine Institute, Duke University Medical Centre, Durham, North Carolina, United States of America, 2 Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America, 3 Department of Surgery, Duke University Medical Centre, Durham, North Carolina, United States of America, 4 Department of Medicine, Duke University Medical Centre, Durham, North Carolina, United States of America, 5 National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin University, Changchun, Jilin, China

* These authors contributed equally to this work.

OPEN ACCESS

Citation: Kumar A, Smith CEP, Giorgi EE, Eudailey J, Martinez DR, Yusim K, et al. (2018) Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. PLoS Pathog 14(4): e1006944. https://doi.org/10.1371/journal.ppat.1006944

Editor: Daniel C. Douek, Vaccine Research Center, UNITED STATES

Received: September 6, 2017
Accepted: February 16, 2018
Published: April 19, 2018

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Data Availability Statement: SGA sequences generated for each mother-infant pair were deposited in Genbank under accession numbers MH012257- MH013187 (http://www.ncbi.nlm.nih.gov/Genbank).

Funding: This work was supported by National Institutes of Health/ National Institute of Allergy and Infectious Diseases (NIH/NAID) Grant 1R01AI22909. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Despite extensive genetic diversity of HIV-1 in chronic infection, a single or few maternal virus variants become the founders of an infant’s infection. These transmitted/founder (T/F) variants are of particular interest, as a maternal or infant HIV vaccine should raise envelope (Env) specific IgG responses capable of blocking this group of viruses. However, the maternal or infant factors that contribute to selection of infant T/F viruses are not well understood. In this study, we amplified HIV-1 env genes by single genome amplification from 16 mother-infant transmitting pairs from the U.S. pre-antiretroviral era Women Infant Transmission Study (WITS). Infant T/F and representative maternal non-transmitted Env variants from plasma were identified and used to generate pseudoviruses for paired maternal plasma neutralization sensitivity analysis. Eighteen out of 21 (85%) infant T/F Env pseudoviruses were neutralization resistant to paired maternal plasma. Yet, all infant T/F viruses were neutralization sensitive to a panel of HIV-1 broadly neutralizing antibodies and variably sensitive to heterologous plasma neutralizing antibodies. Also, these infant T/F pseudoviruses were overall more neutralization resistant to paired maternal plasma in comparison to pseudoviruses from maternal non-transmitted variants (p = 0.012). Altogether, our findings suggest that autologous neutralization of circulating viruses by maternal plasma antibodies select for neutralization-resistant viruses that initiate peripartum transmission, raising the speculation that enhancement of this response at the end of pregnancy could further reduce infant HIV-1 infection risk.

PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006944 April 19, 2018 1 / 26
Author summary

Mother to child transmission (MTCT) of HIV-1 can occur during pregnancy \textit{(in utero)}, at the time of delivery \textit{(peripartum)} or by breastfeeding \textit{(postpartum)}. With the availability of anti-retroviral therapy \textit{(ART)}, rate of MTCT of HIV-1 have been significantly lowered. However, significant implementation challenges remain in resource-poor areas, making it difficult to eliminate pediatric HIV. An improved understanding of the viral population \textit{(escape variants from autologous neutralizing antibodies)} that lead to infection of infants at time of transmission will help in designing immune interventions to reduce perinatal HIV-1 transmission. Here, we selected 16 HIV-1-infected mother-infant pairs from WITS cohort \textit{(from pre anti-retroviral era)}, where infants became infected peripartum. HIV-1 \textit{env} gene sequences were obtained by the single genome amplification \textit{(SGA)} method. The sensitivity of these infant Env pseudoviruses against paired maternal plasma and a panel of broadly neutralizing monoclonal antibodies \textit{(bNAbs)} was analyzed. We demonstrated that the infant T/F viruses were more resistant against maternal plasma than non-transmitted maternal variants, but sensitive to most \textit{(bNAbs)}. Signature sequence analysis of infant T/F and non-transmitted maternal variants revealed the potential importance of V3 and MPER region for resistance against paired maternal plasma. These findings provide insights for the design of maternal immunization strategies to enhance neutralizing antibodies that target V3 region of autologous virus populations, which could work synergistically with maternal ARVs to further reduce the rate of peripartum HIV-1 transmission.

Introduction

Despite the wide success of antiretroviral therapy \textit{(ART)} in lowering mother-to-child transmission \textit{(MTCT)} risk of HIV-1 below 2\%, each year more than 150,000 children become infected worldwide [1]. Even if 90\% maternal ART coverage is reached, approximately 138,000 infant HIV-1 infections will still occur annually [2, 3] due to factors that include: drug non-adherence, breakthrough infections, development of drug resistant viral strains, late presentation of pregnant women to clinical care, and acute infection during late pregnancy or breastfeeding. Mother to child transmission of HIV can occur through three distinct modes: antepartum \textit{(in utero)}, peripartum \textit{(around the time of delivery)}, or postpartum \textit{(via breastfeeding)}. Interestingly, only 30–40\% of infants born to HIV infected mothers acquire HIV-1 in the absence of ART [4]. Thus, maternal factors, such as maternal Env-specific antibodies, may contribute to protecting infants from HIV infection. Maternal factors that are associated with HIV transmission risk include: low maternal peripheral CD4\(^+\) T cell count, and high maternal plasma viral load, delivery mode, and infant gestational age [5–7]. Yet, the role of maternal Env-specific antibody responses and their association with reduced MTCT risk still remains unclear. Previous studies have reported an association between the magnitude of maternal antibody responses and reduced risk of MTCT [8–10]. However, this association has not been universally observed [11–15]. Moreover, it has been observed that variants transmitted to infants can be resistant to neutralization by maternal plasma [16], although other studies have failed to replicate these observations [17–19]. These conflicting results may be due to the small number of subjects included in these studies and study designs that inconsistently control for viral and host factors known to impact transmission risk, such as maternal peripheral CD4\(^+\) T cell counts, plasma viral load, non-identification of T/F viruses, and ART use [20, 21]. Moreover, autologous viruses from a large cohort of HIV-1 infected, transmitting mothers for
assessment of the impact of maternal plasma neutralization activity against her own viruses has not to our knowledge, been investigated. Thus, despite considerable effort, it remains unclear whether maternal antibody responses impact the risk of perinatal transmission of HIV.

We recently completed a maternal humoral immune correlates of protection analysis to identify maternal humoral immune responses associated with protection against peripartum HIV-1 infection using samples from the US-based Women and Infants Transmission (WITS) study [22]. The WITS cohort was enrolled prior to the availability of ART prophylaxis as the clinical standard of care in HIV-infected pregnant mothers and their infants, thereby eliminating the strong impact of ART on perinatal HIV-1 transmission risk and outcome [23, 24]. Additionally, we controlled for established maternal and infant risk factors associated with perinatal transmission, including maternal peripheral CD4+ T cell count, maternal plasma HIV-1 viral load, infant gestational age, and delivery mode by propensity score matching of transmitting and non-transmitting women. The results of this immune correlate analysis indicated an association between high levels of maternal antibodies against the HIV-1 Env glycoprotein third variable loop (V3) and reduced MTCT risk [22]. In addition, and more surprisingly, the ability of maternal plasma to neutralize tier 1 (easy-to-neutralize) viruses but not tier 2 (difficult-to-neutralize) viruses, also predicted decreased risk of perinatal transmission of HIV-1. Yet, vertically transmitted HIV variants have been characterized as more difficult to neutralize tier 2 variants [17, 25–28]. Thus, it was surprising that tier 1 virus neutralizing antibodies were associated with decreased transmission risk. More interestingly, maternal V3-specific monoclonal IgG antibodies obtained from a non-transmitting mother neutralized a large proportion of maternal autologous viruses obtained from her plasma[22], leading to the conclusion that maternal V3-specific non-broadly neutralizing antibodies, which were previously thought to be ineffective at preventing HIV-1 transmission, might indeed play a role in preventing MTCT. In fact, Moody et.al [29] showed that V3 and CD4 binding site (CD4bs) specific monoclonal antibodies obtained from non-pregnant chronically HIV-infected individuals could neutralize a large proportion of autologous circulating viruses obtained from plasma. These V3 and CD4bs-specific autologous virus-neutralizing mAbs exhibited tier 1 neutralization activity but limited heterologous tier 2 virus neutralization, suggesting that measurement of tier 2 heterologous virus neutralization potency of mAbs or plasma does not predict autologous virus neutralization capacity.

In contrast to the extensive genetic diversity of HIV-1 variants in a chronically infected host, acute HIV infections are established by a limited number of T/F viruses [17, 18, 30–33]. This viral genetic bottleneck suggests the selective transmission of a single or homogeneous group of viruses [4]. In the setting of MTCT, maternal or infant immunologic and virologic factors that drive the selective transmission of one or a few HIV variants are not established [34]. As maternal viruses co-circulate with maternal HIV Env-specific antibodies, it is possible that maternal antibodies play a role in selecting maternal escape viruses that may initiate infection in the infant. Therefore, studying unique features of infant T/F viruses and their neutralization-sensitivity determinants to maternal autologous virus neutralizing antibodies may provide insights of the molecular events that lead to virus escape from maternal humoral responses.

The use of broadly neutralizing antibodies as a treatment and/or prevention strategy is currently being explored in adult and infant clinical trials [35, 36]. Among the new generation of bNAb, VRC01 (antibody recognizing CD4bs region) has been able to neutralize about 80% of diverse HIV-1 strains [37, 38]. This has led to studies of VRC01 impact on HIV-1 infection in adults and infants when infused passively, with a phase I study of pharmacokinetics and safety of VRC01 in HIV-exposed newborns currently underway [39]. However, the susceptibility of
infant T/F viruses to bNAbs like VRC01 does not seem to define infant T/F viruses from maternal non-transmitted viruses [17] and administration of a bNAb to chronically-infected mothers is likely to lead to rapid development of resistant viruses [36, 40]. Thus, defining the role of autologous neutralization in MTCT is critical to establishing the utility of active maternal vaccination to further reduce and eliminate infant HIV infections.

In this study, we characterized maternal non-transmitting and infant T/F viruses from 16 HIV-1 clade B infected peripartum transmission mother-infant pairs from the WITS cohort and defined the role of concurrent maternal autologous neutralizing antibodies in selecting for infant T/F viruses. We sought to define if neutralization resistance to paired maternal plasma was a defining feature of infant T/F viruses compared to other circulating non-transmitted maternal variants, which will inform the development of maternal or infant vaccination strategies to further reduced MTCT risk to achieve an HIV-free generation.

Results

Maternal and infant sample characteristics

We selected HIV-1 infected mother-infant transmission pairs from the WITS cohort that met the inclusion criteria of peripartum transmission (infants tested negative for HIV-1 infection at birth by HIV-1 DNA PCR, yet had HIV-1 DNA detectable at one week of age or older; Table 1). These HIV-exposed infants had not reportedly been breastfed [24]. Infant plasma samples available for sequencing were between 16–74 days of age. Five HIV-infected infants with heterogeneous virus populations were excluded from the study due to our inability to confidently infer the infant T/F viral sequences, and selected a total of 16 mother-infant transmission pairs for this study. The maternal plasma viral load of the selected transmitting women ranged from

| Maternal and Infant ID | Year | Maternal Visit of sample collection | Mode of Transmission | Maternal plasma Viral Load (copies/ml) | Maternal Peripheral CD4+ T-cell count (cells/mm³) | Mode of Delivery | Weeks Gestation | Infant Age at sample collection (days) | Infant Viral Load (copies/ml) | Infant Peripheral CD4+ T-cell count (cells/mm³) |
|-----------------------|------|-------------------------------------|---------------------|---------------------------------------|-----------------------------------------------|-----------------|----------------|---------------------------------------|-----------------------------|-----------------------------------------------|
| 100002                | 1993 | Delivery                             | Peripartum          | 305,213                               | 221                                           | Vaginal         | 38             | 16                                    | 1,230,000                   | 3326                           |
| 100014                | 1993 | Delivery                             | Peripartum          | 21,918                                | 692*                                          | C-section       | 31             | 66                                    | 120,000                     | 2012                           |
| 100046                | 1993 | Delivery                             | Peripartum          | 12,635                                | 707                                           | Vaginal         | 40             | 63                                    | 1,025,458                   | 2509                           |
| 100052                | 1993 | Delivery                             | Peripartum          | 23,750                                | 450                                           | Vaginal         | 40             | 34                                    | 333,142                     | 3219                           |
| 100155                | 1992 | Delivery                             | Unknown             | 87,193                                | 318                                           | C-section       | 36             | 60                                    | NA                          | 3609                           |
| 100307                | 1991 | Delivery                             | Unknown             | 139,053                               | 467*                                          | C-section       | 36             | 32                                    | 905,079                     | 2308                           |
| 100383                | 1991 | Delivery                             | Peripartum          | 358,602                               | 244                                           | Vaginal         | 37             | 74                                    | 338,000                     | 2071                           |
| 100504                | 1993 | NA                                   | Unknown             | 68287                                 | 1049                                          | C-Section       | 39             | 30                                    | NA                          | 2742                           |
| 100711                | 1990 | Delivery                             | Unknown             | 4,104†                                | 571*                                          | Vaginal         | 39             | 64                                    | 341,691                     | 1872†                          |
| 100890                | 1991 | Delivery                             | Peripartum          | 368,471                               | 409                                           | Vaginal         | 39             | 26                                    | 192,000                     | 2598                           |
| 100997                | 1991 | Delivery                             | Peripartum          | 175,526                               | 413                                           | Vaginal         | 38             | 20                                    | 46,289†                     | 7048                           |
| 101421                | 1991 | Delivery                             | Peripartum          | 17,370                                | 760                                           | Vaginal         | 37             | 29                                    | 48,783                      | 7628                           |
| 101984                | 1991 | Delivery                             | Peripartum          | 94,087                                | 107                                           | Vaginal         | 36             | 30                                    | 317969                      | 1980                           |
| 102149                | 1993 | Delivery                             | Unknown             | 253,906                               | 373                                           | Vaginal         | 34             | 33                                    | 2,042,124                   | 3181                           |
| 102407                | 1993 | Delivery                             | Peripartum          | 104,922                               | 422                                           | Vaginal         | 40             | 35                                    | 11,100                      | 4677                           |
| 102605                | 1992 | NA                                   | Unknown             | 5684                                  | 337                                           | Vaginal         | 39             | 60                                    | 156639                      | 1360                           |

*Peripheral CD4+ T cell count and/or viral load reported from next available visit, within 2 months from the sample that was obtained for sequencing. NA = Not Available.

†Peripheral CD4+ T cell count and/or viral load reported from 25 weeks of gestation, as CD4+ T cell count and/or viral load was not available at time of delivery.

https://doi.org/10.1371/journal.ppat.1006944.t001
4,104 to 368,471 copies/mL, and peripheral blood CD4⁺ T-cell counts ranged from 107 to 760 cell/mm³. Infant plasma viral loads varied between 11,110 and 2,042,124 copies/mL, and CD4⁺ T-cell counts were between 1,872 and 7,628 cell/mm³. All infants were born via vaginal delivery except for three infants (100014, 100155, 100307) born via Cesarean section, thus potentially representing late in utero transmission. Five infants (100014, 100155, 100307, 102149, and 101984) were born prematurely (31, 34 and 36 weeks respectively), and the remaining infants were born between 37 and 40 weeks of gestation.

Characterization of the complete env gene sequences from paired mother-infant plasma

Infant plasma samples were used to obtain 465 env gene sequences (Table 2). Neighbor-joining phylogenetic trees and highlighter plots of the env sequences from each infant were used to define infant T/F viruses. These analyses showed within-lineage low diversity populations in infant Env sequences and high diversity populations in maternal env sequences (Fig 1, S1 Fig and S2 Fig). In 6 out of 16 (37%) infants we detected 2 or 3 (in case of 100002) genetically distinct T/F variants, one of which was present at higher frequency (primary T/F), while the rest were present at lower frequency (secondary T/Fs). In 10 other infants (67%), we observed only

Table 2. Number of sequences, T/F viruses, and estimated days since most common recent ancestor (MRCA) in infants.

| Maternal and Infant pair ID | Number of Infant envelope gene SGAs | Estimated Number of infant T/F viruses | Infant age at sample collection (days) | Estimated days Since Most Recent Common Ancestor (95% CI) | Notes |
|-----------------------------|-------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------------------|-------|
| 100002                      | 43                                  | 3                                      | 16                                     | 21 (14,28)                                             | Fits a Poisson after removing recombinants. |
| 100014                      | 26                                  | 1                                      | 66                                     | 35 (28,42)                                             | Fits a Poisson. |
| 100046                      | 33                                  | 1                                      | 63                                     | 77 (65,89)                                             | Fits a Poisson after removing hypermutation. |
| 100052                      | 27                                  | 1                                      | 34                                     | 58 (41,75)                                             | Fits a Poisson after removing hypermutation. |
| 100155                      | 23                                  | 1                                      | 60                                     | 63 (50,76)                                             | Fits a Poisson. |
| 100307                      | 31                                  | 2                                      | 32                                     | 27 (18,36)                                             | Fits a Poisson after removing recombinants. |
| 100383                      | 24                                  | 1                                      | 74                                     | 80 (67,92)                                             | Fits a Poisson. |
| 100504                      | 44                                  | 1                                      | 30                                     | 13 (8,18)                                              | Fits a Poisson after removing hypermutation. |
| 100711                      | 26                                  | 1                                      | 64                                     | 27 (17,37)                                             | Fits a Poisson after removing hypermutation. |
| 100890                      | 18                                  | 2                                      | 26                                     | 35 (17,54)                                             | Fits a Poisson after removing recombinants. |
| 100997                      | 32                                  | 2                                      | 20                                     | 19 (13,25)                                             | Fits a Poisson after removing recombinants. |
| 101421                      | 22                                  | 2                                      | 29                                     | 20 (11,29)                                             | Fits a Poisson. |
| 101984                      | 34                                  | 2                                      | 30                                     | 14 (10,19)                                             | Fits a Poisson after removing hypermutation. |
| 102149                      | 27                                  | 1                                      | 33                                     | 43 (31,55)                                             | Fits a Poisson after removing hypermutation. |
| 102407                      | 15                                  | 1                                      | 35                                     | 15 (9,22)                                              | Fits a Poisson. |
| 102605                      | 40                                  | 1                                      | 60                                     | NA                                                    | Does not fit a Poisson, evidence for selection. |

*Number of T/Fs were estimated through visual analysis of highlighter plots and phylogenetic trees after eliminating recombinants and hypermutated sequences.

Days since most recent common ancestor (MRCA) were calculated using the LANL tool Poisson Fitter [https://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/ pfitter.html](https://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/pfitter.html)

https://doi.org/10.1371/journal.ppat.1006944.t002
one T/F virus. With the exception of two infants, all of our samples had over 20 infant sequences, giving us a 90% confidence that we were able to sample all variants with a population frequency of at least 10%. For the two infant samples in which we only had 15 and 18 sequences respectively, we were 90% confident that we were able to sample all variants with a population frequency of 15% or more [26].

A total of 463 env genes were obtained from 16 maternal plasma samples (collected at time of delivery) from transmitting mothers as previously described [26]. Using an algorithm described in the Methods, out of these 463 maternal env variants, we selected 134 SGA variants for env pseudovirus production (5–12 per mother) to represent the env genetic diversity found in the plasma of each transmitting mother at the time of delivery.

**Confirming the timing of infant HIV-1 infection**

As the infants were selected for peripartum transmission, their age at sampling (in days) was also the post-infection time. To confirm the time of infection, all infant alignments were analyzed using the LANL Poisson Fitter tool [41]. For infants that had more than one T/F, only the sequences in the major T/F lineage were used for this analysis. When recombinants and APOBEC enrichment were detected, the timing was calculated after removing recombinants and/or positions enriched for hypermutation [26, 41].

After removing hypermutated sequences and/or recombinants, all but one infant (102605) yielded a good Poisson fit, indicating that the amount of diversity found in these samples was compatible with a random accumulation of mutations as observed in acute infections. The time since the most common ancestor was consistent with transmission at delivery in 9 out of 16 pairs (57%), within the 95% confidence interval of the Poisson Fitter time estimate (Table 2). For the remaining infants, discrepancies between actual vs. predicted transmission timing could be due to a number of factors, including late in utero infection, postpartum infection from unreported breastfeeding, and the model being designed to evaluate an adult rather than infant HIV-1 evolution, which could gather mutations more rapidly due to more robust T cell responses.

Infant 102605 env SGA sequences did not yield a good Poisson fit due to non-random accumulation of non-synonymous mutations (which breaks the model assumption of random accumulation of mutations) at HXB2 positions 752–754 (S3 Fig). According to the LANL immunology database (https://www.hiv.lanl.gov/content/immunology/index), there are five different human CTL epitopes in this region, suggesting that the non-random mutations found in infant 102605 were likely due to selection pressure by T cell responses.

**Neutralization sensitivity and tier classification of the infant T/F viruses**

Twenty-one infant T/F env amplicons including 16 primary T/Fs and 5 secondary T/Fs were used to generate pseudoviruses and their neutralization sensitivity to paired maternal plasma (collected at the time of birth) and a panel of bNAbs was assessed. None of the mothers with the exception of two (100014 and 100504) had non-specific neutralization activity as assessed by neutralization activity against a murine leukemia virus (MLV). Eighteen out of 21 infant T/F Env pseudoviruses (86%) were resistant to paired maternal serum (ID_{50} < 40). Sensitivity of 2 Infant T/F pseudoviruses’ (100014 and 100504) against paired maternal plasma could not be determined with confidence due to higher plasma reactivity against MLV. The T/F virus of infant 100046 was sensitive against paired maternal plasma (Fig 2).

When infant T/F pseudoviruses were tested against the autologous plasma (plasma from the same infant), only 2 T/Fs (from infants 100046 and 100155) showed some sensitivity as per our criteria (ID_{50} > 3X that of MLV), while others were completely resistant. Some infant T/F
Mother to child transmission of HIV-1
pseudoviruses did show sensitivity against their own plasma but were not considered as sensitive due to high reactivity against MLV (S4 Fig).

To determine whether these infant T/F env variants were globally resistant to heterologous plasma neutralization, we performed neutralization tier phenotyping using a standardized panel of heterologous plasma of HIV-1 infected individuals [42]. Thirteen (62%) of 21 infant T/F Env pseudoviruses were classified as tier 2 neutralization phenotype while 3 (14%) of 21 were classified as tier 3 neutralization phenotype, as expected for infant T/F viruses (Fig 2). Remarkably, the remaining 5 (24%) tested were classified as the easier-to-neutralize tier 1b or tier 1a sensitivity, possibly because these variants were uniquely resistant to their paired maternal plasma (Fig 2).

In contrast to the relative resistance to paired maternal plasma neutralization, all the infant T/F viruses were relatively sensitive to second-generation HIV-1 broadly neutralizing antibodies, such as VRC-01, (IC\textsubscript{50} range 0.12–5.0 μg/ml), PGT121 (IC\textsubscript{50} range 0.01–0.13 μg/ml), NIH 45–46 (IC\textsubscript{50} range 0.01–0.28 μg/ml) and first generation bNAb 10E8 (IC\textsubscript{50} range 0.05–0.76 μg/ml) (Fig 3 and S5 Fig). Not surprisingly, the infant T/F Env pseudoviruses were less neutralization sensitive to the less potent first generation broadly neutralizing antibodies b12 (IC\textsubscript{50} range 2.97–25 μg/ml), 4E10 (IC\textsubscript{50} range 1.31–18.73 μg/ml) and 2F5 (IC\textsubscript{50} range 1.01–19.09 μg/ml) (Fig 3). Importantly, all the infant T/F viruses were neutralization sensitive to VRC-01, a bNAb currently being evaluated in clinical trials for use in HIV exposed infants. However, V3 glycan-specific bNAbs, which clustered together in neutralization sensitivity, and NIH45–46 mediated the most neutralization breadth and potency against the infant T/F viruses (Fig 3).

We next calculated the geometric means of both the breadth and potency of the panel of bNAbs against the infant T/F viruses and compared with their potency against other HIV variants as documented in CATNAP (Compile, Analyze and Tally NAb Panels) [43], the Los Alamos National Laboratory (LANL) interface that collects all published immunological data. In general, potency and breadth of the bNAbs against infant T/F viruses followed the mean potency and breadth calculated in CATNAP (p = 0.013 and 0.02 respectively, Spearman correlation test), with one exception: bNAb 2G12 displayed more potent and broad responses in the infants than in the CATNAP collective data (Fig 3).

**Neutralization sensitivity of non-transmitted maternal env variants compared to infant T/F env variants**

Pseudoviruses were prepared from a total of 134 non-transmitted maternal env variants using the promoter PCR method [44] and assessed for neutralization sensitivity against paired maternal plasma, including the maternal non-transmitted variant that was most closely related to the infant T/F variant. Variable neutralization sensitivity to paired maternal plasma was observed in non-transmitted maternal variants, with some of the variants exhibited neutralization sensitivity while others showed complete neutralization resistance (Fig 4). Comparison of neutralization sensitivity between infant T/F Env variants and the identified closest maternal variant within each mother-infant pair revealed no consistent pattern. Over a 2-fold increase in sensitivity was observed for Env pseudoviruses of non-transmitted maternal variants that
were most closely related to infant T/F for 6 infants (100002, 100307, 100052, 102149, 102407 and 102605). In contrast, infant T/F Env pseudoviruses from 3 infants (100014, 100046 and 100504) were more sensitive to maternal plasma than their most closely related maternal variants.

**Fig 2.** Tier phenotyping and neutralization sensitivity of infant T/F pseudoviruses to paired maternal plasma. Dark colors represent viruses that were easily neutralized. The second T/F viruses are marked with asterisks.

https://doi.org/10.1371/journal.ppat.1006944.g002

| Infant T/F    | Virus Tier | Maternal plasma | Maternal plasma vs MLV |
|---------------|------------|-----------------|------------------------|
| 100002i.2.1   | 2          | <20             | <20                    |
| 100014i.2.20  | 2          | 89              | 79                     |
| 100046i.3.2   | 2          | 98              | <20                    |
| 100052i.2.15  | 1B         | 37              | <20                    |
| 100307i.2.26  | 1B         | <20             | <20                    |
| 100307i.2.7*  | 2          | 28              | <20                    |
| 100383i.3.5   | 2          | <20             | <20                    |
| 100711i.3.26  | 2          | <20             | <20                    |
| 100890i.2.1   | 2          | <20             | <20                    |
| 100890i.2.4*  | 1A         | <20             | <20                    |
| 100997i.2.2   | 2          | <20             | <20                    |
| 100997i.2.18* | 3          | <20             | <20                    |
| 101421i.2.23  | 1B         | <20             | <20                    |
| 101421i.2.11* | 2          | 30              | <20                    |
| 102149 i.2.23 | 2          | 29              | <20                    |
| 102407 i.2.1  | 2          | 49              | <20                    |
| 102605i.33    | 2          | 25              | <20                    |
| 100155i.21    | 1B         | 21              | <20                    |
| 100504i.20    | 2          | 126             | 60                     |
| 101984i.10    | 3          | 26              | <20                    |
| 101984i.21*   | 3          | <20             | <20                    |

### ID<sub>50</sub>

- 100002i.2.1: <60
- 100014i.2.20: 60-100
- 100046i.3.2: 101-200

---

| Infant T/F    | Virus Tier | Maternal plasma | Maternal plasma vs MLV |
|---------------|------------|-----------------|------------------------|
| 100002i.2.1   | 2          | <20             | <20                    |
| 100014i.2.20  | 2          | 89              | 79                     |
| 100046i.3.2   | 2          | 98              | <20                    |
| 100052i.2.15  | 1B         | 37              | <20                    |
| 100307i.2.26  | 1B         | <20             | <20                    |
| 100307i.2.7*  | 2          | 28              | <20                    |
| 100383i.3.5   | 2          | <20             | <20                    |
| 100711i.3.26  | 2          | <20             | <20                    |
| 100890i.2.1   | 2          | <20             | <20                    |
| 100890i.2.4*  | 1A         | <20             | <20                    |
| 100997i.2.2   | 2          | <20             | <20                    |
| 100997i.2.18* | 3          | <20             | <20                    |
| 101421i.2.23  | 1B         | <20             | <20                    |
| 101421i.2.11* | 2          | 30              | <20                    |
| 102149 i.2.23 | 2          | 29              | <20                    |
| 102407 i.2.1  | 2          | 49              | <20                    |
| 102605i.33    | 2          | 25              | <20                    |
| 100155i.21    | 1B         | 21              | <20                    |
| 100504i.20    | 2          | 126             | 60                     |
| 101984i.10    | 3          | 26              | <20                    |
| 101984i.21*   | 3          | <20             | <20                    |

### ID<sub>50</sub>

- 100002i.2.1: <60
- 100014i.2.20: 60-100
- 100046i.3.2: 101-200

---

Fig 2. Tier phenotyping and neutralization sensitivity of infant T/F pseudoviruses to paired maternal plasma. Dark colors represent viruses that were easily neutralized. The second T/F viruses are marked with asterisks.

https://doi.org/10.1371/journal.ppat.1006944.g002
Yet, the infant T/F viruses were generally more resistant to the maternal plasma at delivery than the non-transmitted viruses from mothers within each maternal-infant pair, with the exception of 100046. However, since there were only 1 or 2 T/F viruses in each infant, we could not perform statistical analysis to determine if the differences were statistically significant within each pair. To determine whether infant T/F viruses were overall more resistant to maternal plasma than the paired non-transmitted maternal viruses, we employed a 1-sided permutation test to compare the neutralization sensitivity of maternal non-transmitted variants to the infant T/F Env variants. Remarkably, infant T/F Env variants were overall significantly more resistant to paired maternal plasma collected at delivery than non-transmitted maternal Env variants (p = 0.012). Even when excluding the mother-infant pairs with high MLV neutralization (100014 and 100504), the infant T/F Env variants remained more resistant to neutralization than non-transmitted maternal variants (p = 0.005).

To assess whether any particular epitope-specific neutralization sensitivity was distinct in infant T/Fs compared to matched maternal variants, we determined the neutralization sensitivity of 4 bNAbs targeting distinct vulnerable epitopes on HIV-1 Env: VRC-01 (CD4bs-specific), PG9 (V2 glycan-specific), DH429 (V3 glycan-specific), and DH512 (membrane proximal external region–MPER-specific) (Fig 5 and S6 Fig). We used the same 1-sided permutation test described above to assess for differences in neutralization sensitivity to these bNAbs in infant T/Fs versus non-transmitted maternal sequences. Interestingly, we found that infant T/F viruses were significantly more resistant to DH512 (MPER-specific) compared to non-transmitted maternal sequences (p = 0.025 by 1-sided permutation test; p = 0.045 when excluding the two mothers with non-specific neutralization), while all other comparisons yielded no statistical significance (Fig 5 and S6 Fig).

**Signature sequence analysis of infant T/F variants to predict neutralization resistance**

Because DH512 binds to the MPER region, we investigated the amino acid positions within this epitope (positions 662–683) and identified 4 positions that were either associated with higher maternal plasma neutralization ID$_{50}$ (at position 662, amino acid A, K, Q, or S were significantly more resistant than the wild type E, p = 9.9e-05, 1-sided permutation test), lower DH512 IC$_{50}$ (at position 667 and 676, p = 9.9e-04 and 0.003, respectively by 1-sided permutation test), or both (at position 683, amino acid R was significantly more resistant than the wild type K the most frequent AA at this position, p<1e-04 by 1-sided permutation test (Fig 6). To understand the role of amino acids at position 662 and 683 in resistance of infant T/F viruses against maternal plasma, two gp41 mutants R683K and Q662E were generated for 100997i and 102407i T/F env genes respectively. No impact on neutralization sensitivity was observed for the R683K mutant of 100997i whereas the Q662E mutant 102407i T/F was more sensitive to paired maternal plasma than the wild type virus (S7 Fig).

However, when we looked at the Env sequences in individual mother-infant pairs, these amino acid residues that associated with DH512 neutralization resistance were equally distributed across non-transmitted maternal sequences and infant T/F viruses. Therefore, we could not determine if T/F viruses carrying the above resistance-conferring amino acids were more
apt to be transmitted compared to non-transmitted maternal variants. This could be due to the low sequence number within pairs, or suggests that the wild type amino acids at these positions

Fig 4. Neutralization sensitivity of non-transmitted maternal variants and infant T/F pseudoviruses to paired maternal plasma. (A) Neutralization sensitivity of infant T/F viruses were compared to non-transmitted maternal viruses for each mother–infant pair and (B) neutralization sensitivity were compared between all infant T/F viruses and all non-transmitted maternal variants together. Maternal non-transmitted variants are shown by black dots and infant T/F viruses are represented by blue triangles (1st T/F) and blue dots (2nd T/F). Maternal variant sequences were selected following an algorithm to represent different motifs that diverge from the infant T/F (see Methods). Black horizontal lines represent the median of the ID₅₀ of maternal and infant sequences. The P value was determined by one sided permutation test.

https://doi.org/10.1371/journal.ppat.1006944.g004
are associated with DH512 neutralization resistance, but not necessarily transmission. However, infant T/F viruses and maternal variants that have the same sequence in the MPER region can have more than threefold differences in DH512 MPER-associated antibody neutralization, indicating that there are residues in the flanking regions that impact MPER-associated neutralization.

**V3 loop amino acid signature sequence analysis and neutralization sensitivity to paired maternal plasma**

As maternal V3-specific IgG binding and tier 1 virus neutralizing responses were predictive of MTCT risk in this cohort [22], we explored possible signatures of neutralization resistance to paired maternal plasma in the V3 region. We examined the highly variable N and C-terminal region amino acid residues K305Q, I307T, H308T, R315Q, F317L, A319T, and D322R (Fig 7), 3 of which (K305Q, I307T, and H308T) have previously been identified critical targets of the V3-specific IgG responses associated with reduced MTCT risk [45]. Comparing non-transmitted maternal sequences and infant T/F viruses, we found position K305R to be significantly associated with higher sensitivity to paired maternal plasma (p < 0.001 by 1-sided permutation test). At position 308, sequences carrying mutations from the consensus amino acid H (N, P, S or T) were significantly associated with higher neutralization resistance to paired maternal plasma (p < 0.001 by 1-sided permutation test). This discrepancy could partially be due to the heterogeneity at amino acid residue position 308. Yet, 6 out of 14 transmitting mother-infant pairs exhibited distinct amino acid residues at position 308 from the more frequently occurring histidine (Fig 7), suggesting variability at this position could be overrepresented in transmitting pairs. However, as for the MPER residues, we observed that these amino acids were equally distributed across non-transmitted maternal and infant T/F virus sequences, indicating that none of these amino acid residues were directly involved with transmission risk.

**Discussion**

While maternal and infant ART has considerably reduced rates of MTCT, pediatric HIV infection remains a significant public health problem in areas of high HIV prevalence, with up to 16% of HIV-infected women still transmitting the virus to their infant globally [1]. It is likely that a maternal or infant HIV-1 vaccine will be required to eliminate pediatric HIV [46]. However, a better understanding of factors that affect HIV-1 transmission in the setting of MTCT

---

**Fig 5. Neutralization sensitivity of maternal and infant viruses to bNAbs DH512 and VRC-01.** IC\textsubscript{50} was determined for maternal non-transmitted variants (black dots) and infant T/F variants (triangles and circles in blue) as neutralized by VRC-01 and DH512. Black horizontal lines represent the median of the IC\textsubscript{50} bNAbs. Dashed lines represent the highest Ab concentration (5μg/ml) used in the experiment.

https://doi.org/10.1371/journal.ppat.1006944.g005
will be required to develop vaccination strategies that can block HIV-1 transmission. Recent findings published by our group demonstrated that maternal V3 loop-specific and tier 1 virus-neutralizing antibody responses both correlated and were independently associated with reduced MTCT risk. Moreover, we established that V3-specific antibodies in maternal plasma could neutralize maternal autologous viral variants circulating in plasma [22, 29]. To examine the potential role of maternal Env-specific Ab responses in driving the viral genetic bottleneck of MTCT, we aimed to define if neutralization resistance to maternal autologous virus-neutralizing antibodies is a defining feature of infant T/F viruses compared to circulating maternal non-transmitted plasma variants.

Although, env gene sequences derived from the same T/F viruses were very homogenous in all infants, we observed evolutionary selection in some infant env sequences as indicated by the presence of same non-synonymous mutations in multiple env gene sequences (Fig 1B). Six out of 16 (37%) peripartum-infected infants were infected by at least 2 T/F viruses. Infection with multiple T/F viruses occurs in approximately 19–24% of heterosexual HIV infections [26, 47, 48], and 12–38% of homosexual infections [49–51], whereas up to 60% of infections that occur through intravenous drug use involve multiple T/Fs [52]. Thus, the rate of multiple T/F transmissions in this mother-infant cohort is in line with or slightly higher than sexual transmission modes, but lower than that of transmission via intravenous drug use. While it is well established that a genetic bottleneck occurs in the setting of MTCT, the determinants that drive the selection of one or multiple T/F viruses are less clear [4]. Importantly, the lack of maternal ART prophylaxis around the time of delivery in the WITS cohort could contribute to the observed high rate of multiple T/F viruses, potentially stemming from a larger virus inoculum in this cohort compared to ARV-treated mothers. Notably, these infant T/F viruses uniformly represented a minor variant of the maternal viral population Env variants, indicating that maternal antibodies that can block infant virus transmission will need to target minor circulating variants.

A greater understanding of virologic characteristics of infant T/F viruses will also be important for developing immune-based strategies to prevent MTCT. BNAb neutralization analysis of all infant T/F viruses showed that they were significantly more resistant to DH512 (MPER

![Fig 6. Comparison of neutralization sensitivity of maternal and infant viruses to DH512. Comparison of paired maternal plasma and MPER specific bNAb DH512 maternal non-transmitted sequences (black dots) and infant T/F sequences (blue triangles) between sequences that carry the wild type amino acid at HXB2 positions 662, 676, 676, and 683, compared with those that carry a mutant. These four positions were chosen because they yielded a significant association with either maternal plasma responses (i.e. sequences carrying the mutant were statistically significantly more resistant to maternal plasma) or with DH512 responses (i.e. sequences carrying the mutant were statistically significantly more resistant to DH 512) in the MPER epitope. P-values were obtained using a 1-sided permutation test (see Methods). Gray boxes represent median and quartiles of the responses.](https://doi.org/10.1371/journal.ppat.1006944.g006)

![Fig 7. Frequency plot of the V3 region sequences of mother and infant T/F viruses. Weblogo plot showing frequency of amino acids in the V3 region was made using the Analyze Align tool from the LANL website. Positions were numbered based on HXB2 amino acid sequence. Amino acid positions identified in the signature sequence analysis are marked at the top of the plot.](https://doi.org/10.1371/journal.ppat.1006944.g007)
region specific antibody) than non-transmitted maternal variants, we investigated role of
MPER region based neutralizing antibodies of maternal plasma in evolution of infant T/F [53].
Signature sequence analysis of the MPER sequences showed that E662 and K683 were associ-
ated with sensitivity of infant T/F viruses to maternal plasma. Site Directed mutagenesis analy-
sis in the MPER region of two infant T/F env genes from 100997i R683K and 102407i Q662E
and sensitivity against paired maternal plasma was tested. Results showed that identified resi-
dues in the MPER region epitope indeed had a role in escape of infant T/F viruses for one
infant T/F (102407i) but not the other T/F virus (100997i). However, roles of other regions or
structures in recognition of this MPER epitope could not be ruled out. This result supports our
signature sequence analysis and yet also indicates the potential importance of other Env
regions in escape of infant T/F viruses from the maternal plasma selection pressure.

As maternal V3-specific IgG responses predicted reduced risk of transmission in this
cohort, we investigated V3 loop residues in the maternal and infant viruses and how they
related to paired maternal plasma neutralization sensitivity. Despite the association between
maternal V3-specific IgG responses targeting the C terminal region and reduced MTCT risk
in this cohort [45], we did not find amino acid residues within the C terminal region to be
associated neutralization resistance to paired maternal plasma. Instead, we found that mater-
nal non-transmitted and infant T/F viruses carrying N, P, S or T at the N terminal region
amino acid residue position 308 were more neutralization resistant to paired maternal plasma.
These seemingly disparate findings could partly be explained by several reasons. Firstly, N ter-
rnal amino acid residues 308 and 309 have been shown to interact with C terminal amino
acid residue 317, and this interaction leads to the stabilization of the V3 loop [54, 55]. Thus,
the disruption of intra-peptide interactions at either the N and or C terminal region could lead
to altered neutralization sensitivity of viruses to paired maternal V3-specific IgG plasma
responses. Secondly, it should be noted that in this study, we compared maternal non-trans-
mitted circulating viruses to infant T/F viruses in 16 transmitting mother infant pairs, whereas
we previously defined the potentially-protective role of maternal V3-specific IgG binding and
neutralizing responses by comparing transmitting and non-transmitting women in a larger
number (n = 248) of subjects in the WITS cohort [22, 45]. Therefore, there may be differences
in the fine-specificity and neutralizing function of V3-specific IgG responses within these 16
peripartum transmitting mothers compared to n = 165 non-transmitting women from the
WITS cohort. In addition, there could be differences in the V3 loop accessibility in these 16
transmitting mothers compared to non-transmitting women in this cohort and thus explain-
ing the lack of a V3 loop amino acid residue signature that is associated with neutralization
resistance. Previous work has shown that V3 loop accessibility to maternal neutralizing anti-
odies may be modulated by distal amino acid residues within gp120 or gp41 [15]. For exam-
ple, specific glycosylation sites within the V1 loop may alter V3 loop accessibility to
V3-specific neutralizing antibodies [56]. Moreover, interactions between C2 and V3 may stabi-
lize the structure of the HIV-1 Env [57], as demonstrated with the recent crystal structure elu-
cidation of the SOSIP trimer [58].

In contrast to previous studies that examined the neutralization sensitivity of randomly
selected or non-paired infant or maternal viruses, here we defined the neutralization sensitivity
of paired infant T/F viruses and maternal non-transmitted variants. Moreover, this study
accounted for phylogenetic relationships of infant T/F viruses and maternal non-transmitted
variants to represent the diverse maternal virus lineage pools. Furthermore, we carefully con-
trolled for confounders such as transmission mode and disparate maternal and infant sample
testing. Moreover, as the WITS cohort was enrolled and followed prior to the availability of
ART to prevent MTCT, viral evolution in this cohort is not influenced by ART selection pres-
sure. With this robust study design, our analysis demonstrated that infant T/F viruses are
mostly resistant to concurrent maternal plasma, suggesting that infant T/F viruses are defined by neutralization resistance to paired maternal neutralizing antibodies. This work confirms previous studies that have made this prediction based on smaller studies or with less well-defined maternal and infant virus variants [16, 59, 60]. Yet, Miligan et al [61] recently showed that neutralization resistant viruses do not predict MTCT risk in a breastfeeding transmission setting. However, as our analysis focused on peripartum transmission, there may be distinct virologic or immunologic determinants in peripartum and postpartum HIV transmission. Yet, an important and novel observation gleaned from this study is that infant T/F viruses’ neutralization resistance to maternal plasma is not predictive of neutralization resistance to heterologous plasma. Remarkably, the tiered categorization of infant T/F viruses ranged from easy to neutralize tier 1a viruses, to very difficult to neutralize tier 3 viruses, suggesting that heterologous plasma neutralization resistance is not a defining feature of infant T/F viruses. Specifically, 24% of infant T/F viruses characterized in this study were classified as tier 1b or tier 1a variants by a standard panel of heterologous plasma [42], consistent with the hypothesis that these infant T/F viruses may be specifically resistant to maternal antibodies that co-evolved with the transmitted variants.

The majority of infant T/F viruses were neutralization sensitive to a number of second generation broadly neutralizing antibodies (Fig 5). Clinical studies to analyze safety and pharmacokinetics ability of VRC01 showed that it was well tolerated [40]. Further, VRC01 was able to protect non-human primates from infection [62, 63]. Our findings are clinically relevant, as they suggest that infant passive immunization with second generation broad and potent bNAbs to prevent HIV-1 transmission could be an effective strategy to block MTCT. The uniform sensitivity of these newly characterized clade B infant T/F viruses to VRC01 neutralization indicates that these viruses would be effectively neutralized by VRC01, and that clade B infant virus transmission may be blocked by VRC01. Interestingly, there is an ongoing passive immunization clinical trial of high-risk, HIV-exposed infants with VRC01 (https://clinicaltrials.gov/ct2/show/record/NCT02256631).

To our knowledge, this is the largest study that has characterized infant T/F and maternal viruses and their neutralization sensitivity to maternal neutralizing responses. Our study specifically addresses whether infant T/F viruses are defined by their neutralization sensitivity to maternal autologous virus neutralizing antibodies in peripartum MTCT of HIV.

MTCT is a unique setting in which protective antibodies only need block autologous viral variants circulating in blood to which the infant is exposed. The observation that infant T/F viruses are neutralization resistant compared to non-transmitted maternal variants suggests that the development of a maternal vaccine that boosts maternal autologous virus neutralizing responses may be a viable strategy to further reduce MTCT risk. Maternal Env immunization regimens with closely related, but not identical, Env to maternal circulating virus populations may elicit antibodies that target maternal autologous virus pool through the well-described immune phenomenon of ‘original antigenic sin’ [64, 65]. Our central finding that resistance to maternal plasma neutralization is more common in infant T/F viruses than non-transmitted maternal viruses has important implications in designing maternal Env vaccination strategies that can enhance maternal autologous virus neutralization and synergize with current ART treatment strategies help achieve a reduced rate of perinatal virus transmission.

Materials and methods
Study subjects and sample collection
Maternal and infant pairs from the WITS cohort that met the following criteria were selected: peripartum transmission, infant plasma samples from < 2.5 months of age, and maternal
samples available from around delivery. Peripartum transmission was defined by a negative PCR result or negative culture from peripheral blood samples collected within 7 days of birth with subsequent positive result 7 days after birth (Table 1).

**Ethics statement**

Samples used in this study were obtained from an existing cohort named as Women Infant Transmission Study (WITS). WITS cohort samples were received as de-identified material and were deemed as research not involving human subjects by Duke University Institutional Review Board (IRB). The reference number for that protocol and determination is Pro00016627.

**Viral RNA extraction and SGA analysis**

Viral RNA was purified from the plasma sample from each patient by the Qiagen QiaAmp viral RNA mini kit and subjected to cDNA synthesis using 1X reaction buffer, 0.5 mM of each deoxynucleoside triphosphate (dNTP), 5 mM DTT, 2 U/mL RNaseOUT, 10 U/mL of SuperScript III reverse transcription mix (Invitrogen), and 0.25 mM antisense primer 1. R3.B3R (5’-ACTACTTGAAGCACTCAAGGCAAGCTTTATTTG-3’), located in the nef open reading frame. The resulting cDNA was end-point diluted in 96 well plates (Applied Biosystems, Inc.) and PCR amplified using Platinum Taq DNA polymerase High Fidelity (Invitrogen) so that < 30% of reactions were positive in order to maximize the likelihood of amplification from a single genome. A second round of PCR amplification was conducted using 2μl of the first round products as template. 07For7 (5’-AAATTAYAAAAATTTCAAAAATTTCGGGTTTATTACAG-3’) and 2.R3.B6R (5’- TGA AGCAGCGAAGCTTTATTAGGC-3’) were used as primer pair in the first round of PCR amplification step, followed by a second round with primers VIF1 (5’- GGGTTTATTACAGGGACAGCAG -3’)(nt 5960–5983 in the HXB2 tat coding region) and Low2c (5’- TGAGGCT TAAGCAGTGGGTT CC-3’) (nt 9413–9436 in HXB2 nef). PCR was carried out using 1X buffer, 2 mM MgSO4, 0.2 mM of each dNTP, 0.2μM of each primer, and 0.025 U/μl Platinum Taq High Fidelity polymerase (Invitrogen) in a 20μl reaction. Round 1 amplification conditions were 1 cycle of 94˚C for 2 minutes, 35 cycles of 94˚C for 15 seconds, 58˚C for 30 seconds, and 68˚C for 4 minutes, followed by 1 cycle of 68˚C for 10 minutes. Round 2 conditions were one cycle of 94˚C for 2 minutes, 45 cycles of 94˚C for 15 seconds, 58˚C for 30 seconds, and 68˚C for 4 minutes, followed by 1 cycle of 68˚C for 10 minutes. Round 2 PCR amplicons were visualized by agarose gel electrophoresis and sequenced for envelope gene using an ABI3730xl genetic analyzer (Applied Biosystems). The final amplification 3’-half genome product was ~4160 nucleotides in length exclusive of primer sequences and included all of rev and env gp160, and 336 nucleotides of nef. Partially overlapping sequences from each amplicon were assembled and edited using Sequencher (Gene Codes, Inc). Sequences with double peaks per base read were discarded. Sequences with one double peak were retained as this most likely represents a Taq polymerase error in an early round of PCR rather than multiple template amplification; such sequence ambiguities were read as the consensus nucleotide. Sequence alignments and phylogenetic trees were constructed using ClustalW and Highlighter plots were created using the tool at https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html.

SGA sequences generated for each mother-infant pair were deposited in Genbank under accession numbers MH012257- MH013187 (http://www.ncbi.nlm.nih.gov/Genbank/).
Sequence alignment

All maternal and infant envelope sequences were aligned using the Gene Cutter tool available at the Los Alamos National Laboratory (LANL) website (http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html) and then refined manually. Full-length envelope sequences were manually edited in Seaview [66]. The infant T/F env virus sequences were identified by analysing phylogenetic trees and highlighter plots, and infant consensus sequences of the major T/F lineage were generated using the LANL Consensus Maker tool (http://www.hiv.lanl.gov/content/sequence/CONSENSUS/consensus.html). For infants that were infected by 2 or more distinct T/F viruses, the highlighter plots and phylogenetic trees were rooted on the consensus of the major variant.

Inference of infant T/F env sequences

Maternal and infant envelope alignments were characterized using Bio-NJ phylogeny (Mega 6 Software) and highlighter plot. The number of infant T/F viruses was determined by visual inspection of both phylogenetic trees and highlighter plots of infant-maternal env sequence alignments. Hypermutation was also evaluated using the tool Hypermut (http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html). Sequences with significant hypermutation (p<0.1) were removed from the alignment and not included in further analysis. When a sample was found to be overall enriched for hypermutation [26], positions within the APOBEC signature context were removed (Table 2). All 16 infant infections were acute and we were able to time the infection using the Poisson Fitter method after removing putative recombinants and/or hypermutated sequences as described above. Days since infant infection were calculated using the Poisson Fitter tool (http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/pfitter.html) which estimates the time since infection based on the accumulation of random mutations from the most recent common ancestor (MRCA) [41]. For infants infected with 2 or more T/F viruses, only the major variant was analyzed to obtain the time since the infection. The defined mutation rate was 2.16e-5. Values were reported in days with a 95% confidence interval and a goodness-of-fit p-value.

Cloning of infant T/F env SGA sequences

Amplicons from the first round PCR product that matched the infant consensus sequence (T/F virus sequence) were ligated into pcDNA3.1 Directional Topo vectors (Invitrogen) by introducing a–CACC 5’ end via a PCR reaction with the primers Rev19 (5’- ACTTTTTGACCAC TTGCCACCCAT-3’) and Env1A (5’-caccTTAGGCATC TCCT ATGGCAGGAAGAAG-3’). Phusion High-Fidelity PCR Master Mix with HF Buffer was used according to the manufacturer’s instructions (New England BioLabs). Plasmids were then transformed into XL10 gold chemically competent Escherichia coli cells. Cultures were grown at 37˚C for 16 hours. Colonies were selected for growth, and plasmids were minipreped and quality controlled by restriction enzyme digestion using BamHI and Xhol (New England BioLabs). Plasmids containing an insert of correct size were sequenced to confirm 100% sequence homology with the original env infant consensus sequence. Plasmids were then prepared by Megaprep (Qiagen) kit and re-sequenced to confirm. For three infants, 100046, 100383 and 101580, no SGA sequences matched 100% of nucleotides in the consensus sequence. Therefore site-directed mutagenesis on a single nucleotide was performed to generate an env gene identical to the consensus sequence. Primers for site directed mutagenesis were designed using Agilent’s QuikChange primer design program and Agilent’s QuikChange II XL kit was used. Sequencing of the clones was done to ensure 100% homology with the infant consensus sequence.
Pseudovirus preparation

Env pseudoviruses were prepared by transfection in HEK293T (ATCC, Manassas, VA) cells with 4μg of env plasmid DNA and 4μg of env-deficient HIV plasmid DNA (SG3Δenv) using the FuGene 6 transfection reagent (Roche Diagnostics) in a T75 flask. Two days after transfection, the culture supernatant containing pseudoviruses was harvested, filtered, aliquoted, and stored at -80˚C. An aliquot of frozen pseudovirus was used to measure the infectivity in TZM-bl cells. 20μl of pseudovirus was distributed in duplicate to 96-well flat bottom plates (Co-star). Then, freshly trypsinized TZM-bl cells were added (10,000 cells/well in Dulbecco’s modified Eagle’s medium (DMEM)-10% fetal bovine serum (FBS) containing HEPES and 10μg/ml of DEAE-dextran). After 48 h of incubation at 37˚C, 100μl of medium was removed from the wells. 100μl of luciferase reagent was added to each well and incubated at room temperature for 2 min. 100μl of the lysate was transferred to a 96-well black solid plate (Costar), and the luminescence was measured using the Bright-Glo luminescence reporter gene assay system (Promega).

Neutralization assays

Neutralizing antibody activity was measured in 96-well culture plates by using Tat-regulated luciferase (Luc) reporter gene expression to quantify reductions in virus infection in TZM-bl cells. TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program, as contributed by John Kappes and Xiaoyun Wu. Assays were performed with HIV-1 Env-pseudotyped viruses as described previously [67]. Test samples were diluted over a range of 1:20 to 1:43740 in cell culture medium and pre-incubated with virus (~150,000 relative light unit equivalents) for 1 hr at 37˚C before addition of cells. Following a 48-hr incubation, cells were lysed and Luc activity determined using a microtiter plate luminometer and BriteLite Plus Reagent (Perkin Elmer). Neutralization titers are the sample dilution (for serum/plasma) or antibody concentration (for sCD4, purified IgG preparations and monoclonal antibodies) at which relative luminescence units (RLU) were reduced by 50% compared to RLU in virus control wells after subtraction of background RLU in cell control wells. Serum/plasma samples were heat-inactivated at 56˚C for 1 hr prior to assay. Pseudovirus made with Env glycoprotein from a murine leukemia virus (SVA.MLV) was used as a negative control [42]. A response was considered positive if the plasma ID50 against infant T/F viruses was at least 3 times higher than the ID50 of the SVA.MLV pseudovirus.

Env pseudovirus tier phenotyping assay

Neutralization titers (ID50s) were determined essentially as described above using five plasma samples from HIV+ individuals in chronic infection. The geometric mean titer (GMT) was calculated in Microsoft Excel and tier phenotype was determined by comparing these values to the GMTs of standard panels of viruses representing tier 1A, tier 1B and tier 2 viruses [42, 68] using the same five HIV+ plasma samples.

Sequence selection algorithm

To select maternal non-transmitted variants and capture the most divergent sequences from the infant T/F, we devised an algorithm as follows. The algorithm finds the most variable positions in the amino acid alignment and ranks all sequences with respect to the frequencies at these positions. Sequences are then selected starting from the most divergent based on motif coverage as observed in the alignment and in the phylogenetic tree (in other words, if a group
of diverging sequences all share the same motif, only one in the group and/or tree node is selected).

**Statistical analysis**

To test whether infant transmitted viruses were statistically significantly more resistant to maternal plasma than non-transmitted maternal sequences, we devised a 1-sided permutation test. At each iteration, we randomly assigned the “transmitted” status to any one sequence in each infant-mother pair, and then ranked the remaining sequences in the pair according to maternal plasma responses. All ranks across all pairs were then summed. We repeated this randomization 1,000 times and then calculated the p-value as the percentage of sum of ranks that were above the observed sum of ranks, out of all randomizations performed. This method is robust, as it does not make any underlying assumption of the distribution of the maternal plasmas, and it preserves the within mother-infant correlation of the data. The same algorithm was used to test whether specific amino acid positions conferred resistance to maternal plasma and/or antibodies. This time the “transmitted” status that was reshuffled at each iteration, was the wild type amino acid. All programming for the sequence selection algorithm and permutation test was done on the R platform [69].

**Supporting information**

S1 Fig. Phylogenetic tree and highlighter plot of the env sequence from mother infant pairs with sample ID 100002, 100046, 100155, 100307, 100383 and 100504. Infant sequences are labeled in red circles and maternal sequences are labeled in blue squares. (TIF)

S2 Fig. Phylogenetic tree and highlighter plot of the env sequence from mother infant pairs with sample ID 100711, 100890, 101421, 101984, 102149 and 102407. Infant sequences are labeled in red circles and maternal sequences are labeled in blue squares. (TIF)

S3 Fig. Phylogenetic tree and highlighter plot of sequences from the mother infant pair 102605. Infant sequences are labeled in red and maternal sequences are labeled in blue. The non-random accumulation of synonymous mutations in the infant (which caused the Poisson Fitter analysis to fail) is evident on the right as marked by red box. (TIF)

S4 Fig. Neutralization sensitivity of infant T/F pseudoviruses to heterologous broadly neutralizing antibodies. Dark colors represent viruses that were easily neutralized. The second T/F viruses are indicated with asterisks. (TIF)

S5 Fig. Neutralization sensitivity of infant T/F pseudoviruses to autologous infant plasma. Dark colors represent viruses that were easily neutralized. The second T/F viruses are indicated with asterisks. (TIF)

S6 Fig. Neutralization sensitivity of maternal and infant pseudoviruses to bNAbs PG9 and DH429. IC_{50} of maternal non-transmitted variants (black dots) and infant T/F viruses (blue triangles and circles) to two antibodies PG9 and DH429. Black horizontal lines represent the median of the IC_{50} of maternal and infant sequences. Dashed lines represent the detection limit. (TIF)
S7 Fig. Neutralization analysis of signature amino acids in the MPER region. (A) Schematic of gp41 region indicates the position of mutated amino acids mutated. (B) Neutralization sensitivity of infant T/F viruses from 100997i and 102407i and their mutants to paired maternal plasma. ID_{50} of infant T/F variants (blue bars) and their point mutants (red bars). E662 and K683 are the signature sequence sites in the MPER region of HIV-1 envelope gene. FP = Fusion Peptide, NHR = N-terminal heptad repeat, CHR = C-terminal heptad repeat, MPER = Membrane Proximal External Region.

Acknowledgments
We acknowledge Nathan Vandergrift in selecting peripartum transmission samples from the WITS cohort. We would also like to acknowledge the support of Pediatric HIV/AIDS Cohort Study (PHACS) team for their management of the Women and Infant Transmission study cohort samples.

Author Contributions
Conceptualization: Feng Gao, Sallie R. Permar.
Data curation: Amit Kumar, Claire E. P. Smith, Joshua Eudailey, David R. Martinez, Ayooluwa O. Douglas, Lisa Stamper, Erin McGuire, Celia C. LaBranche, Sallie R. Permar.
Formal analysis: Amit Kumar, Claire E. P. Smith, Elena E. Giorgi, David R. Martinez, Karina Yusim, Celia C. LaBranche, David C. Montefiori, Genevieve G. Fouda, Feng Gao, Sallie R. Permar.
Funding acquisition: Sallie R. Permar.
Investigation: Amit Kumar, Feng Gao, Sallie R. Permar.
Methodology: Amit Kumar, Claire E. P. Smith, Elena E. Giorgi, Joshua Eudailey, David R. Martinez, Karina Yusim, Ayooluwa O. Douglas, Lisa Stamper, Erin McGuire, Celia C. LaBranche, David C. Montefiori, Genevieve G. Fouda, Sallie R. Permar.
Resources: Amit Kumar, Elena E. Giorgi, David R. Martinez, Karina Yusim, Sallie R. Permar.
Software: Elena E. Giorgi.
Supervision: Sallie R. Permar.
Validation: Sallie R. Permar.
Writing – original draft: Amit Kumar, Claire E. P. Smith, Elena E. Giorgi, David R. Martinez, Karina Yusim, Feng Gao.
Writing – review & editing: Feng Gao, Sallie R. Permar.

References
1. UNAIDS. Progress Report on the Global Plan: towards the elimination of new HIV infections among children and keeping their mothers alive. UNAIDS, Geneva, Switzerland. 2015.
2. Mahy M, Stover J, Kiragu K, Hayashi C, Akwara P, Luo C, et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Transm Infect. 2010; 86 Suppl 2:i48–55.
3. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002; 288(2):189–98. PMID: 12095383

4. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 1992; 255 (5048):1134–7. PMID: 1546316

5. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999; 341(6):394–402. https://doi.org/10.1056/NEJM199905303410602 PMID: 10432324

6. Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr. 2010; 54(1):27–34. https://doi.org/10.1097/QAI.0b013e3181caea89 PMID: 20065861

7. Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005; 38(1):87–95. PMID: 15608531

8. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, Filho EC, Calvet G, et al. Neutralization titres and vertical HIV-1 transmission. Scand J Immunol. 2002; 56(6):642–4. PMID: 12472677

9. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, Joao Filho EC, Calvet G, et al. Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity. Scand J Immunol. 2001; 53(3):302–9. PMID: 11251889

10. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis. 1993; 168(1):207–10. PMID: 8515110

11. Braibant M, Barin F. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context? Retrovirology. 2013; 10:103. https://doi.org/10.1186/1742-4690-10-103 PMID: 24099103

12. Blish CA, Blay WM, Haigwood NL, Overbaugh J. Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res. 2007; 5(6):578–87. PMID: 18045114

13. Mutucumurana CP, Eudalkey J, McGuire EP, Vandergrift N, Tegha G, Chasela C, et al. Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals. Clin Vaccine Immunol. 2017; 24(8).

14. Overbaugh J. Mother-infant HIV transmission: do maternal HIV-specific antibodies protect the infant? PLoS Pathog. 2014; 10(8):e1004283. https://doi.org/10.1371/journal.ppat.1004283 PMID: 25144453

15. Zolla-Pazner S, Cohen SS, Boyd D, Kong XP, Seaman M, Nussenzweig M, et al. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. J Virol. 2015; 90(2):636–49. https://doi.org/10.1128/JVI.01645-15 PMID: 26491157

16. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006; 80(2):835–44. https://doi.org/10.1128/JVI.80.2.835-844.2006 PMID: 16378885

17. Fouda GG, Mahlokozer a T, Salazar-Gonzalez JF, Salazar MG, Learn G, Kumar SB, et al. Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of non-transmitted breast milk variants. Retrovirology. 2013; 10:3. https://doi.org/10.1186/1742-4690-10-3 PMID: 23305422

18. Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, Montefiori DC, et al. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol. 2011; 85(16):8253–62. https://doi.org/10.1128/JVI.00197-11 PMID: 21593171

19. Thenin S, Samleerat T, Tavernier E, Ngo-Giang-Huong N, Jourdain G, Lallemant M, et al. Envelope glycoconjugates of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties. Virology. 2012; 426(1):12–21. https://doi.org/10.1016/j.virol.2012.01.017 PMID: 22310702

20. Bulterys M, Ellington S, Courtis AP. HIV-1 and breastfeeding: biology of transmission and advances in prevention. Clin Perinatol. 2010; 37(4):807–24, ix-x. https://doi.org/10.1016/j.cip.2010.08.001 PMID: 21078452

21. Bulterys PL, Dalai SC, Katzenstein DA. Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission. Clin Perinatol. 2010; 37 (4):739–50, viii. https://doi.org/10.1016/j.cip.2010.08.003 PMID: 21078447
22. Perrmar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, et al. Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. J Clin Invest. 2015; 125(7):2702–6. https://doi.org/10.1172/JCI81593 PMID: 26053661

23. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010; 362(24):2271–81. https://doi.org/10.1056/NEJMoai911486 PMID: 20554982

24. Rich KC, Fowler MG, Mofenson LM, Abboud R, Pitt J, Díaz C, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics. 2000; 105(1):e8. PMID: 10617775

25. Baalwa J, Wang S, Parrish NF, Decker JM, Keele BF, Learn GH, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013; 436(1):33–48. https://doi.org/10.1016/j.virol.2012.10.009 PMID: 23123038

26. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008; 105(21):7552–7. https://doi.org/10.1073/pnas.0802203105 PMID: 18490657

27. Nakamura KJ, Heath L, Sobrera ER, Wilkinson TA, Semrau K, Kankasa C, et al. Breast milk and intrauterine transmission of HIV-1 select for envelope variants with unique molecular signatures. Retrovirology. 2017; 14(1):6. https://doi.org/10.1186/s12977-017-0331-z PMID: 28122636

28. Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev. 2013; 254(1):143–69. https://doi.org/10.1111/imr.12074 PMID: 23772619

29. Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, et al. Strain-specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015; 18(3):354–62. https://doi.org/10.1016/j.chom.2015.08.006 PMID: 26355218

30. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, et al. Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol. 2002; 76(23):11953–9. https://doi.org/10.1128/JVI.76.23.11953-11959.2002 PMID: 12414937

31. Derdeyn CA, Decker JM, Bollibet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004; 303 (5666):2019–22. https://doi.org/10.1126/science.1093137 PMID: 15044802

32. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol. 1993; 67(6):3345–56. PMID: 8497055

33. Gantt S, Carlsson J, Heath L, Bull ME, Shetty AK, Mutsvangwa J, et al. Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol. 2010; 84(20):10812–9. https://doi.org/10.1128/JVI.00543-10 PMID: 20660189

34. Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K. Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology. 2011; 8:67. https://doi.org/10.1186/1742-4690-8-67 PMID: 21843318

35. Haynes BF BT. Broadly Neutralizing Antibodies and the Development of Vaccines. JAMA. 2015; 313 (24):2419–20. https://doi.org/10.1001/jama.2015.2427 PMID: 26103022

36. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenweig MC. Antibodies in HIV-1 vaccine development and therapy. Science. 2013; 341(6151):1199–204. https://doi.org/10.1126/science.1241144 PMID: 24031012

37. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016; 533(7601):105–9. https://doi.org/10.1038/nature17677 PMID: 27120156

38. Lynch RM, Boritz E, Coates EE, DeZure A, Maddon P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015; 7 (319):319ra206. https://doi.org/10.1126/scitranslmed.aad5752 PMID: 26702094

39. Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, et al. HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. PLoS Med. 2014; 11(4):e1001616. https://doi.org/10.1371/journal.pmed.1001616 PMID: 24714363

40. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015; 182(3):289–301. https://doi.org/10.1111/cei.12692 PMID: 26332605
41. Giorgi EE, Funkhouser B, Athreya G, Perelson AS, Korber BT, Bhattacharya T. Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics. 2010; 11:532. https://doi.org/10.1186/1471-2105-11-532 PMID: 20973976

42. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010; 84(3):1439–52. https://doi.org/10.1128/JVI.02108-09 PMID: 19939925

43. Yoon H, Macke J, West AP Jr., Foley B, Bjorkman PJ, Korber B, et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 2015; 43(W1):W213–9. https://doi.org/10.1093/nar/gkv404 PMID: 26044712

44. Kirchherr JL, Lu X, Kasongo W, Chalwe V, Mwananyanda L, Musonda RM, et al. High throughput functional analysis of HIV-1 env genes without cloning. J Virol Methods. 2007; 143(1):104–11. https://doi.org/10.1016/j.jviromet.2007.02.015 PMID: 17416428

45. Martinez DR, Vandergrift N, Douglas AO, McGuire E, Bainbridge J, Nicely NI, et al. Maternal Binding and Protection of Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. J Virol. 2017; 91(9). https://doi.org/10.1128/JVI.02422-16 PMID: 28202762

46. Fouda GG, Cunningham CK, Permar SR. Infant HIV-1 vaccines: supplementing strategies to reduce maternal-child transmission. JAMA. 2015; 313(15):1513–4. https://doi.org/10.1001/jama.2015.1382 PMID: 25989044

47. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA, et al. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis. 2004; 190(7):1355–9. PMID: 15346349

48. Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, et al. Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol. 2004; 78(13):7279–83. https://doi.org/10.1128/JVI.78.13.7279-7283.2004 PMID: 15194805

49. Chen Y, Li N, Zhang T, Huang X, Cai F, Vandergrift N, et al. Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China. J Acquir Immune Defic Syndr. 2015; 69(4):403–12. https://doi.org/10.1097/QAI.0000000000000649 PMID: 25886933

50. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog. 2010; 6(5):e1000890. https://doi.org/10.1371/journal.ppat.1000890 PMID: 20485520

51. Kazenova E, Laga V, Gromov K, Lebedeva N, Zhukova E, Pronin A, et al. Genetic Variants of HIV Type 1 in Men Who Have Sex with Men in Russia. AIDS Res Hum Retroviruses. 2017.

52. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol. 2010; 84(12):6241–7. https://doi.org/10.1128/JVI.00777-10 PMID: 20375173

53. Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, et al. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. J Virol. 2012; 86(8):4129–38. https://doi.org/10.1128/JVI.06359-11 PMID: 22301151

54. Liu BJ, Snodgrass JS, Mehta P, Diouf M, Chertow C, Kellems RE, et al. Reduced Peripartum HIV-1 Transmission Risk. J Virol. 2017; 91(9). https://doi.org/10.1128/JVI.02422-16 PMID: 28202762

55. Losman B, Bolmstedt A, Schonning A, Bjorndal A, Westin C, Fenyo EM, et al. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. AIDS Res Hum Retroviruses. 2001; 17(11):1067–76. https://doi.org/10.1089/088922201300343753 PMID: 11485624

56. Willey RL, Martin MA. Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120. J Virol. 1993; 67(6):3639–43. PMID: 8497072

57. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013; 342(6165):1484–90. https://doi.org/10.1126/science.1246527 PMID: 24179160

58. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol. 2006; 80(13):6525–33. https://doi.org/10.1128/JVI.02658-05 PMID: 16775339
60. Rainwater SM, Wu X, Nduati R, Nedellec R, Mosier D, John-Stewart G, et al. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res. 2007; 5(2):189–97. PMID: 17346133

61. Milligan C, Omenda MM, Chohan V, Odem-Davis K, Richardson BA, Nduati R, et al. Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk. MBio. 2016; 7(1):e02221–15. https://doi.org/10.1128/mBio.02221-15 PMID: 26838723

62. Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med. 2016; 22(4):362–8. https://doi.org/10.1038/nm.4063 PMID: 26998834

63. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014; 88(21):12669–82. https://doi.org/10.1128/JVI.02213-14 PMID: 25142607

64. Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol. 2009; 183(5):3294–301. https://doi.org/10.4049/jimmunol.0900398 PMID: 19648276

65. Park MS, Kim JI, Park S, Lee I, Park MS. Original Antigenic Sin Response to RNA Viruses and Antiviral Immunity. Immune Netw. 2016; 16(5):261–70. https://doi.org/10.4110/in.2016.16.5.261 PMID: 27799871

66. Gouy M, Guindon S, Gascuel O. SeaView version 4: A muliplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol. 2010; 27(2):221–4. https://doi.org/10.1093/molbev/msp259 PMID: 19854763

67. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009; 485:395–405. https://doi.org/10.1007/978-1-59745-170-3_26 PMID: 19020839

68. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicted neutralizing antibodies. J Virol. 2005; 79(16):10108–25. https://doi.org/10.1128/JVI.79.16.10108-10125.2005 PMID: 16051804

69. R DCT. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2008.